Moreover, OAT-1746 treatment affects the expression of genes involved in leukocyte chemotaxis (Ccl2, Ccl7, Ccl17) and supporting glioma migration and invasion (Cme1, S100a4 and Mmp14). The gene discussed is CCL2; the disease is central nervous system cancer.